TW Stock Analysis Is Available! Go Get Discount!

Alterity therapeutics ltd - adr

US StockHealth Care

ATHE AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.

ATHE Current Performance


Alterity therapeutics ltd - adr


Avg of Sector



Top 10 High Relevance to ATHE

  • TIL Instil bio inc
    Value -Trend 4Swing Trading 2Whale Interest 2Dividend 1Market Cap 41.1M
    See more

ATHE Profile

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Price of ATHE